Compare AbbVie Inc (ABBV) vs Allstate Corp (ALL) Price & Performance

AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.

The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.

Allstate (ALL) trades at $251.46, up 0.45% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 5.49, net income margin of 17.98%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 earnings anticipation and dividend declarations, reinforcing positive sentiment.

Outlook remains favorable given valuation discounts and earnings strength, though risks include potential hurricane impacts and market volatility. Analyst consensus leans bullish with a $249.50 price target, suggesting near-term stability with upside potential from continued operational execution.